Optimizing Tolerability, Quality of Weight Loss & Personalized Therapies to Drive Competitive Drug Development
As obesity drug development enters a defining new chapter, the race is no longer about developing the next GLP-1, but delivering the next breakthrough in tolerability, muscle preservation, patient adherence, precision medicine, and long-term outcomes. With hundreds of obesity assets in development and billions of dollars invested in the space, 2026 is a pivotal moment for companies to differentiate their pipelines, benchmark their strategies, and secure their position in the market.
The 3rd Obesity & Weight Loss Drug Development Summit West is where the industry's most innovative pharma and biotech leaders come together to answer the questions that will shape the next decade of obesity therapeutics. While many events focus on clinical readouts or broad discussions around obesity care, this summit is dedicated to the practical challenges and strategic decisions driving drug development success.
Bringing together 80+ senior executives, and decision-makers, this intimate, industry-focused forum offers unparalleled opportunities to exchange insights, build meaningful partnerships, and understand what today's innovation really means for tomorrow's therapies. If you're serious about advancing next-generation obesity therapeutics, this is the room you need to be in.
This is a terrific program to understand the current landscape of obesity and metabolic disease, challenges, and opportunities, as well as gaining insights into emerging breakthroughs.
John Dobak, Chief Executive Officer, ClicBio
Taking part in this meeting provides an important opportunity to advance the conversation beyond weight loss alone and toward the metabolic, muscular, and functional outcomes that ultimately determine long-term health.
Hans Keirstead, Chairman, Immunis
The 3rd Obesity & Weight Loss Drug Development Summit West provides a valuable opportunity to network with peers and maintain a close connection to the latest scientific thinking shaping the field.
John Liles, Vice President, Biology & Translational Science, Moonwalk Biosciences
Explore the Full Event Guide
- Hear from 80% + Speakers at VP+ Level
- Join 10+ Companies Unveiling New Data
- Learn from 14+ New Speaking Companies
- 90%+ New Biopharma Speaking Individuals with new Case Studies
- Free* Attendance for Representatives from Biopharma
2026 Partners
Expertise Partner
Innovaton Partners
Event Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of obesity drug development and make critical connections during our dedicated networking sessions.